Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr 29:12:657457.
doi: 10.3389/fphar.2021.657457. eCollection 2021.

Gaseous Mediators as a Key Molecular Targets for the Development of Gastrointestinal-Safe Anti-Inflammatory Pharmacology

Affiliations
Review

Gaseous Mediators as a Key Molecular Targets for the Development of Gastrointestinal-Safe Anti-Inflammatory Pharmacology

Aleksandra Danielak et al. Front Pharmacol. .

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) represent one of the most widely used classes of drugs and play a pivotal role in the therapy of numerous inflammatory diseases. However, the adverse effects of these drugs, especially when applied chronically, frequently affect gastrointestinal (GI) tract, resulting in ulceration and bleeding, which constitutes a significant limitation in clinical practice. On the other hand, it has been recently discovered that gaseous mediators nitric oxide (NO), hydrogen sulfide (H2S) and carbon monoxide (CO) contribute to many physiological processes in the GI tract, including the maintenance of GI mucosal barrier integrity. Therefore, based on the possible therapeutic properties of NO, H2S and CO, a novel NSAIDs with ability to release one or more of those gaseous messengers have been synthesized. Until now, both preclinical and clinical studies have shown promising effects with respect to the anti-inflammatory potency as well as GI-safety of these novel NSAIDs. This review provides an overview of the gaseous mediators-based NSAIDs along with their mechanisms of action, with special emphasis on possible implications for GI mucosal defense mechanisms.

Keywords: carbon monoxide; gastrointestinal safety; hydrogen sulfide; inflammation; nitric oxide; non-steroidal anti-inflammatory drugs.

PubMed Disclaimer

Conflict of interest statement

JW was employed by Antibe Therapeutics, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Pathomechanism of NSAIDs-induced gastrointestinal damage.
FIGURE 2
FIGURE 2
Possible mechanisms of action of NO-, H2S-releasing NSAIDs, NOSH-NSAIDs or NSAIDS applied with CO donors.
FIGURE 3
FIGURE 3
Chemical structures of selected NO-NSAIDs.
FIGURE 4
FIGURE 4
Chemical structures of selected H2S-NSAIDs.
FIGURE 5
FIGURE 5
Chemical structures of selected NOSH-NSAIDs.
FIGURE 6
FIGURE 6
Chemical structure of CO-ASS.

Similar articles

Cited by

References

    1. Al-Swayeh O. A., Clifford R. H., Del Soldato P., Moore P. K. (2000). A Comparison of the Anti-inflammatory and Anti-nociceptive Activity of Nitroaspirin and Aspirin. Br. J. Pharmacol. 129 (2), 343–350. 10.1038/sj.bjp.0703064 - DOI - PMC - PubMed
    1. Ambrosini M. V., Mariucci G., Rambotti M. G., Tantucci M., Covarelli C., Angelis L. D., et al. (2005). Ultrastructural Investigations on Protective Effects of NCX 4016 (Nitroaspirin) on Macrovascular Endothelium in Diabetic Wistar Rats. J. Submicrosc Cytol. Pathol. 37 (2), 205–213. http://www.ncbi.nlm.nih.gov/pubmed/16335593. - PubMed
    1. Bacchi S., Palumbo P., Sponta A., Coppolino M. F. (2012). Clinical Pharmacology of Non-steroidal Anti-inflammatory Drugs: A Review. Aiaamc 11 (1), 52–64. 10.2174/187152312803476255 - DOI - PubMed
    1. Bakalarz D., Surmiak M., Yang X., Wójcik D., Korbut E., Śliwowski Z., et al. (2021). Organic Carbon Monoxide Prodrug, BW-CO-111, in Protection against Chemically-Induced Gastric Mucosal Damage. Acta Pharmaceutica Sinica B 11 (2), 456–475. 10.1016/j.apsb.2020.08.005 - DOI - PMC - PubMed
    1. Bełtowski J. (2015). Hydrogen Sulfide in Pharmacology and Medicine – an Update. Pharmacol. Rep. 67 (3), 647–658. 10.1016/j.pharep.2015.01.005 - DOI - PubMed

LinkOut - more resources